Varonis Systems announced Q3 2026 revenues of $189.5 million, up from $161.6 million a year earlier, driven by a 47% increase in SaaS revenues to $185.1 million. Despite revenue growth, the company reported a GAAP operating loss of $47.7 million, wider than the prior year's loss, due to ongoing investments and transition from term licenses to SaaS. Non-GAAP operating income improved to $7.6 million, reflecting operational progress. Varonis holds $937.8 million in cash and securities and is not providing future guidance due to its pending acquisition by Proofpoint.
Varonis Systems' Q3 2026 financial results provide context for readers interested in technology companies. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 150 priced US tech stocks, 94 rose and 53 fell. Notable movers include AXTI at USD 52.12 with a 1-day change of +8.13%, SHOP at USD 143.56 down -8.10%, and VERI at USD 0.56 down -7.99%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
